Biogen Alzheimer's drug hits roadblocks with some hospitals, insurers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Biogen (BIIB) PT Lowered to $400 at BofA Securities
July 16, 2021 8:25 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on Biogen (NASDAQ: BIIB) to $400.00 (from $415.00) while maintaining a Neutral rating on commercial headwinds.
... MoreExpert Panel Unanimously Decides Biogen's (BIIB) Aduhelm Offers no Patient Benefit
July 15, 2021 5:38 PM EDT(Updated - July 15, 2021 6:00 PM EDT)
Shares of Biogen (NASDAQ: BIIB) are losing 3% after-hours following a unanimous vote by a panel of prominent medical experts claiming the company's recently approved Alzheimer's drug Aduhelm offers no patient benefit.
In a recent meeting held by the... More
